The Next Frontier for China Biopharma: From Pipeline Assets to Development Platforms

Peter is an executive with 25 years of experience in life sciences consulting and industry, with past positions including at Bayer and GSK. Trained in U.S. Market Access, his focus for the past several years is on strategy, insights, and analytics. As part of this scope, Peter developed launch playbooks, product positioning, and insights frameworks, and built advanced analytics and data functions for big pharma. Peter is a frequent conference chair and speaker. He obtained his Doctorate fmo the Free University of Berlin and holds an MBA from Columbia Business School

Hannah leads the Pharma Strategic Intelligence team at GlobalData; she brings over 14 years of experience spanning the pharmaceutical industry and clinical settings. She has deep expertise in both medical and commercial strategy across multiple therapy areas, supporting products at various stages of development, as well as forecasting and market assessment to support investment decisions for early pipeline assets. Hannah has worked on several global product launches, competitive readiness initiatives, and external engagement strategies, including advisory boards and leading international conference activities.

George is a Strategic Intelligence Analyst at GlobalData contributing to quantitative and qualitative analysis reports on disruptive themes and technologies. George focuses on the impact of themes, such as Rare Disease, Orphan Designated Drugs, and AI in Drug Discovery within the Pharma, Healthcare and Medical Services sector. Prior to joining GlobalData, George studied for an MSc in Drug Discovery and Pharma Management at University College London (UCL).

Nancy Wang is Principal in GlobalData’s CI consulting group, based in London. She brings 15 years of experience, including in commercial strategy and competitive intelligence. Nancy has delivered numerous projects, including for several top-tier global pharma, covering China industry trends, through primary CI, market research, secondary intelligence, and analysis with deep market knowledge, and leveraging an extensive team of GD sources and partners. She is a recognized China expert and obtained her PhD from Cambridge University.